Kiora Pharmaceuticals Shares Outstanding History (KPRX)
Kiora Pharmaceuticals reported 3.8M shares outstanding at the end of fiscal 2025.
View full Kiora Pharmaceuticals company overviewKiora Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.8M | 760,951 | +25.36% |
| 2024 | 2024-12-31 | 3.0M | 2.9M | +3057.52% |
| 2023 | 2023-12-31 | 95,036.202 | 72,879.736 | +328.93% |
| 2022 | 2022-12-31 | 22,156.466 | 18,251.749 | +467.43% |
| 2021 | 2021-12-31 | 3,904.717 | 2,191.497 | +127.92% |
| 2020 | 2020-12-31 | 1,713.22 | 455.913 | +36.26% |
| 2019 | 2019-12-31 | 1,257.307 | 320.408 | +34.20% |
| 2018 | 2018-12-31 | 936.898 | 617.639 | +193.46% |
| 2017 | 2017-12-31 | 319.259 | 131.838 | +70.34% |
| 2016 | 2016-12-31 | 187.421 | 45.761 | +32.30% |
| 2015 | 2015-12-31 | 141.66 | — | — |
Kiora Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.4M | 993,676 | +28.94% |
| Q1 2026 | 2026-03-31 | 4.0M | 992,681 | +33.08% |
| Q4 2025 | 2025-12-31 | 3.8M | 760,951 | +25.36% |
| Q3 2025 | 2025-09-30 | 3.4M | 432,703 | +14.42% |
| Q2 2025 | 2025-06-30 | 3.4M | 462,946 | +15.58% |
| Q1 2025 | 2025-03-31 | 3.0M | 30,243 | +1.02% |
| Q4 2024 | 2024-12-31 | 3.0M | −23.7M | −88.78% |
| Q3 2024 | 2024-09-30 | 3.0M | 2.7M | +826.67% |
| Q2 2024 · Jun 30 | 2024-06-30 | 3.0M | 2.9M | +3025.70% |
| Q2 2024 · Jun 11 | 2024-06-11 | 3.0M | 2.9M | +3032.37% |
| Q2 2024 · Jun 10 | 2024-06-10 | 26.7M | 26.6M | +31267.42% |
| Q1 2024 | 2024-03-31 | 323,826.106 | 300,155.133 | +1268.03% |
| Q4 2023 | 2023-12-31 | 95,036.132 | 72,879.666 | +328.93% |
| Q3 2023 | 2023-09-30 | 94,833.865 | 81,525.657 | +612.60% |
| Q2 2023 | 2023-06-30 | 85,232.128 | 81,203.009 | +2015.40% |
| Q1 2023 | 2023-03-31 | 23,670.973 | 19,766.254 | +506.21% |
| Q4 2022 | 2022-12-31 | 22,156.466 | 18,251.747 | +467.43% |
| Q3 2022 | 2022-09-30 | 13,308.208 | 9,417.275 | +242.03% |
| Q2 2022 | 2022-06-30 | 4,029.119 | 1,840.598 | +84.10% |
| Q1 2022 | 2022-03-31 | 3,904.719 | 1,716.198 | +78.42% |
| Q4 2021 | 2021-12-31 | 3,904.719 | 2,191.499 | +127.92% |
| Q3 2021 | 2021-09-30 | 3,890.933 | 2,464.352 | +172.75% |
| Q2 2021 | 2021-06-30 | 2,188.521 | 761.939 | +53.41% |
| Q1 2021 | 2021-03-31 | 2,188.521 | 761.939 | +53.41% |
| Q4 2020 | 2020-12-31 | 1,713.22 | 455.913 | +36.26% |
| Q3 2020 | 2020-09-30 | 1,426.581 | 490.34 | +52.37% |
| Q2 2020 | 2020-06-30 | 1,426.581 | 581.581 | +68.83% |
| Q1 2020 | 2020-03-31 | 1,426.581 | 583.431 | +69.20% |
| Q4 2019 | 2019-12-31 | 1,257.307 | 414.098 | +49.11% |
| Q3 2019 | 2019-09-30 | 936.241 | 132.525 | +16.49% |
| Q2 2019 | 2019-06-30 | 845 | 60.918 | +7.77% |
| Q1 2019 | 2019-03-31 | 843.15 | 523.891 | +164.10% |
| Q4 2018 | 2018-12-31 | 843.208 | 523.95 | +164.11% |
| Q3 2018 | 2018-09-30 | 803.716 | 485.428 | +152.51% |
| Q2 2018 | 2018-06-30 | 784.082 | 465.794 | +146.34% |
| Q1 2018 | 2018-03-31 | 319.259 | 118.014 | +58.64% |
| Q4 2017 | 2017-12-31 | 319.259 | 131.838 | +70.34% |
| Q3 2017 | 2017-09-30 | 318.288 | 140.949 | +79.48% |
| Q2 2017 | 2017-06-30 | 318.288 | 152.678 | +92.19% |
| Q1 2017 | 2017-03-31 | 201.245 | 46.836 | +30.33% |
| Q4 2016 | 2016-12-31 | 187.421 | 45.761 | +32.30% |
| Q3 2016 | 2016-09-30 | 177.339 | 35.728 | +25.23% |
| Q2 2016 | 2016-06-30 | 165.61 | 45.784 | +38.21% |
| Q1 2016 | 2016-03-31 | 154.409 | 36.903 | +31.40% |
| Q4 2015 | 2015-12-31 | 141.66 | — | — |
| Q3 2015 | 2015-09-30 | 141.611 | — | — |
| Q2 2015 | 2015-06-30 | 119.826 | — | — |
| Q1 2015 | 2015-03-31 | 117.506 | — | — |
Kiora Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Kiora Pharmaceuticals's shares outstanding moved from 1,713.22 to 3.8M, a change of 3.8M. The latest reported quarter, Q2 2026, shows 4.4M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kiora Pharmaceuticals filings at SEC.gov ↗